| __timestamp | Bio-Techne Corporation | Novo Nordisk A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 30945000 | 13762000000 |
| Thursday, January 1, 2015 | 40853000 | 13608000000 |
| Friday, January 1, 2016 | 45187000 | 14563000000 |
| Sunday, January 1, 2017 | 53514000 | 14014000000 |
| Monday, January 1, 2018 | 55329000 | 14805000000 |
| Tuesday, January 1, 2019 | 62413000 | 14220000000 |
| Wednesday, January 1, 2020 | 65192000 | 15462000000 |
| Friday, January 1, 2021 | 70603000 | 17772000000 |
| Saturday, January 1, 2022 | 87140000 | 24047000000 |
| Sunday, January 1, 2023 | 92493000 | 32443000000 |
| Monday, January 1, 2024 | 96664000 | 48062000000 |
Igniting the spark of knowledge
In the ever-evolving landscape of biotechnology and pharmaceuticals, innovation is the lifeblood of progress. This chart offers a fascinating glimpse into the research and development (R&D) spending trends of two industry giants: Novo Nordisk A/S and Bio-Techne Corporation, from 2014 to 2023.
Novo Nordisk, a leader in diabetes care, has consistently outpaced Bio-Techne in R&D investment, with expenditures peaking at approximately $32 billion in 2023. This represents a staggering 135% increase from 2014. In contrast, Bio-Techne, a key player in life sciences, has shown a steady growth trajectory, with R&D spending rising by over 210% during the same period, reaching nearly $97 million in 2023.
While Novo Nordisk's spending dwarfs that of Bio-Techne, the latter's rapid growth underscores its commitment to innovation. Notably, data for 2024 is incomplete, highlighting the dynamic nature of this sector.
Research and Development Expenses Breakdown: Novo Nordisk A/S vs Mesoblast Limited
Research and Development: Comparing Key Metrics for Novo Nordisk A/S and Supernus Pharmaceuticals, Inc.
Comparing Innovation Spending: Novo Nordisk A/S and Dynavax Technologies Corporation
Research and Development Expenses Breakdown: Novo Nordisk A/S vs Novavax, Inc.
Novo Nordisk A/S vs Viridian Therapeutics, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Johnson & Johnson and Bio-Techne Corporation
Analyzing R&D Budgets: Gilead Sciences, Inc. vs Bio-Techne Corporation
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Bio-Techne Corporation
Research and Development: Comparing Key Metrics for Bio-Techne Corporation and Apellis Pharmaceuticals, Inc.
Research and Development Investment: Bio-Techne Corporation vs Rhythm Pharmaceuticals, Inc.
R&D Insights: How Bio-Techne Corporation and ADMA Biologics, Inc. Allocate Funds
R&D Insights: How Bio-Techne Corporation and Wave Life Sciences Ltd. Allocate Funds